8.4  0.36 (4.48%)		12-01 16:00
Open: 8.01 High: 8.415 Volume: 1,097,979		Pre. Close: 8.04 Low: 7.74 Market Cap: 635(M)

Short term
Mid term
Targets	6-month :	10.17	1-year :	11.88
Resists	First :	8.71	Second :	10.17
Pivot price	7.71
Supports	First :	7.4	Second :	6.59
MAs	MA(5) :	7.91	MA(20) :	7.83
	MA(100) :	13.06	MA(250) :	14.11
MACD	MACD :	-0.4	Signal :	-0.6
%K %D	K(14,3) :	72.9	D(3) :	57.5
RSI	RSI(14): 52.3
52-week	High :	22.93	Low :	6.57

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ETNB ] has closed above the upper band by 14.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 71.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	8.36 - 8.39	8.39 - 8.42
Low:	7.88 - 7.92	7.92 - 7.95
Close:	7.98 - 8.04	8.04 - 8.09

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Mon, 27 Nov 2023
89bio Announces New Positive Long-Term Data from the ENLIVEN ... - BioSpace

Tue, 21 Nov 2023
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx ... - Yahoo Finance

Thu, 09 Nov 2023
89bio Inc (ETNB) Reports Increased R&D and G&A Expenses in Q3 ... - Yahoo Finance

Wed, 01 Nov 2023
Do Traders Think 89bio Inc (ETNB) Can Keep Climbing Wednesday? - InvestorsObserver

Thu, 26 Oct 2023
89Bio's Low Price Presents An Opportunity (NASDAQ:ETNB) - Seeking Alpha

Wed, 11 Oct 2023
RBC Capital Maintains 89bio (ETNB) Outperform Recommendation - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	76 (M)
Shares Float	59 (M)
Held by Insiders	0.7 (%)
Held by Institutions	102 (%)
Shares Short	5,430 (K)
Shares Short P.Month	6,330 (K)

EPS	-1.8
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.42
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-25.7 %
Return on Equity (ttm)	-45 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.79
Qtrly Earnings Growth	0 %
Operating Cash Flow	-122 (M)
Levered Free Cash Flow	-79 (M)

PE Ratio	-4.67
PEG Ratio	-0.4
Price to Book value	1.54
Price to Sales	0
Price to Cash Flow	-5.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.